CIDP - Chronic Inflammatory Demyelinating PolyneuropathyMOVE CIDPNCT07882797
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy
An observational study of CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
Trial summary
This prospective, longitudinal study aims to evaluate the usefulness of high-resolution whole-body motion data captured by wearable sensors to assess functional status and longitudinal changes in CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) patients undergoing treatment. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- What is being tested?
- Xsens motion suit
- Type of treatment
- Medical device
- How many people
- 50 participants
- Where
- 1 siteGermany
- Study dates
- 23 Oct 2026to 1 Jan 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: CIDP patients treated at the University Hospital in Düsseldorf.
Who may be able to join
- Diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to current EAN/PNS diagnostic criteria
- Age ≥18 years
- Ability to understand and perform the standardized movement protocol safely
- Written informed consent prior to study participation
Who cannot join
- Additional neurological diseases that substantially affect motor function as evaluated by the principal investigator
- Relevant orthopedic or rheumatological conditions that substantially influence movement performance as determined by the principal investigator
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
University Hospital Düsseldorf
Düsseldorf, North Rhine-Westphalia, 40225
Dr. med. Lars Masanneck, 0049 211 8117887, neuro-trials@med.uni-duesseldorf.de
About this study
Official title: Prospective Observational Cohort Study to Quantitatively Characterize Movement Patterns and Their Longitudinal Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy Using an Xsens Inertial Measurement Suit and Smartwatch Sensors
This prospective, longitudinal study aims to evaluate the usefulness of high-resolution whole-body motion data captured by wearable sensors to assess functional status and longitudinal changes in CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) patients undergoing treatment. Close clinical monitoring will complement sensor-based movement data to investigate whether detailed kinematic measures can capture motor impairments and changes that are only partially reflected by established clinical scores.
Read the detailed description
CIDP is a rare chronic immune-mediated neurological condition that can lead to muscle weakness, sensory disturbances, gait impairment, and limitations in everyday activities. Due to the heterogeneous clinical presentation of CIDP, objective assessment of functional status and longitudinal changes remains challenging. Established clinical measures such as INCAT, I-RODS, MRC sum score, and grip strength provide important information on disability and motor function but may not capture subtle, regional, or multidimensional changes in movement.
Consequently, this study aims to evaluate high-resolution whole-body motion data to assess functional status and longitudinal changes in patients with CIDP. Firstly, sensor-based movement measures will be compared to established clinical scores, strength measurements, and patient-reported outcomes. Secondly, explorative analyses will aim to investigate whether longitudinal changes in movement patterns reflect changes in functional status and whether distinct movement phenotypes can be identified.
Data captured by the whole-body motion-sensing system (Xsens) includes three-dimensional kinematic parameters describing the movement of individual joints and body segments. These include joint angles, movement velocities, range of motion, acceleration, coordination, and side-to-side symmetry. Based on these parameters, multidimensional movement "fingerprints" will be derived to characterize individual motor function. Blood samples will additionally be collected for the analysis of potential biomarkers, including serum neurofilament light chain (sNfL), glial fibrillary acidic protein (GFAP), and proteomic data. The investigators aim to determine whether sensor-based movement patterns can capture regional and gradual motor impairments and whether they provide additional information beyond established clinical outcome measures.
Optionally, explorative analyses will investigate whether characteristic movement phenotypes, such as predominantly upper- or lower-limb, proximal or distal, or asymmetric impairment patterns, can be identified from the sensor data.
Patients will be recruited in Düsseldorf.
- Being tested
- Xsens motion suit
- Keywords
- DHT, CIDP, Wearables, Motion suit, motion capture, movement patterns, whole-body motion analysis, Xsens, movement phenotypes
- Medical subject headings
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Xsens motion suitDevice
Non-interventional observational study with whole-body motion assessment to assess functional status and longitudinal changes in patients with CIDP.
| Study group | Role | What they receive |
|---|---|---|
| CIDP patiens | CIDP patients undergoing any treatment. Receives: Device: Xsens motion suit |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in joint angle distributions during standardized movement tasks
Change in joint angle distributions across predefined joints and standardized movement tasks from baseline to 6 and 12 months. Joint angle distributions will be characterized using prespecified parameters describing joint kinematics. Changes in these parameters will be assessed at each follow-up visit relative to baseline.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in movement velocity
Quantitative assessment of joint and limb movement velocities during standardized motor tasks
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in movement-space volume
Quantification of the three-dimensional movement space achieved by individual joints or body segments during standardized movement tasks
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in coordination patterns
Quantitative assessment of intersegmental and inter-joint coordination during standardized movements
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in side-to-side movement symmetry
Quantification of asymmetries between the left and right sides during standardized upper- and lower-limb movements
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in proximal versus distal movement patterns
Quantification of differences in movement characteristics between proximal and distal joints and body segments
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in upper- versus lower-limb movement patterns
Quantification of differences in movement characteristics between upper and lower extremities
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in whole-body movement fingerprint
Longitudinal change in the multidimensional sensor-derived movement fingerprint
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and the I-RODS score
Correlation between sensor-derived joint angle distributions and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and the I-RODS score
Correlation between sensor-derived movement velocity and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and the I-RODS score
Correlation between sensor-derived whole-body movement fingerprint and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and the INCAT disability score
Correlation between sensor-derived joint angle distributions and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and the INCAT disability score
Correlation between sensor-derived movement velocity and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and the INCAT disability score
Correlation between sensor-derived whole-body movement fingerprint and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and the MRC sum score
Correlation between sensor-derived joint angle distributions and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and the MRC sum score
Correlation between sensor-derived movement velocity and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and the MRC sum score
Correlation between sensor-derived whole-body movement fingerprint and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and handgrip strength
Correlation between sensor-derived joint angle distributions and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and handgrip strength
Correlation between sensor-derived movement velocity and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and handgrip strength
Correlation between sensor-derived whole-body movement fingerprint and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Secondary outcomes (7)
Change in Pittsburgh Sleep Quality Index (PSQI)
Patient-reported assessment of subjective sleep quality
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in Fatigue Severity Scale (FSS)
Patient-reported assessment of the severity and impact of fatigue
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in WHOQOL-BREF
Patient-reported assessment of health-related quality of life across multiple domains
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in blood-based biomarkers
Blood-based analyses including serum neurofilament light chain (sNfL), glial fibrillary acidic protein (GFAP), and proteomic analyses
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in standardized walking performance
Sensor-based assessment of movement characteristics during standardized walking tasks, including gait-related kinematic parameters
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in Timed Up and Go performance
Sensor-based assessment of whole-body kinematics during the Timed Up and Go task, including sit-to-stand, walking, turning, and stand-to-sit components
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in sit-to-stand performance
Sensor-based assessment of whole-body movement during standardized sit-to-stand and transfer tasks
Measured: Baseline (V1), Month 6 (V2), Month 12 (V3)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start23 Oct 2026
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CIDP - Chronic Inflammatory Demyelinating PolyneuropathyStudies of the same condition, open and under way.
- More trials run by Heinrich-Heine University, DuesseldorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. med. Lars Masanneck, Heinrich-Heine University, Duesseldorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07882797
- Sponsor's protocol ID
- 2023-2402_01
- Acronym
- MOVE CIDP
- Status last verified
- Oct 2026
- First submitted
- 22 Sep 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Cohort Study to Quantitatively Characterize Movement Patterns and Their Longitudinal Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy Using an Xsens Inertial Measurement Suit and Smartwatch Sensors
- ClinicalTrials.gov ID
- NCT07882797
- Acronym / sponsor ID
- MOVE CIDP / 2023-2402_01
- Keywords
- DHT, CIDP, Wearables, Motion suit, motion capture, movement patterns, whole-body motion analysis, Xsens
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Heinrich-Heine University, DuesseldorfUniversity, hospital or other
- Study start
- 23 Oct 2026 (actual)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Jan 2028 (estimated)
- First posted
- 20 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, longitudinal study aims to evaluate the usefulness of high-resolution whole-body motion data captured by wearable sensors to assess functional status and longitudinal changes in CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) patients undergoing treatment. Close clinical monitoring will complement sensor-based movement data to investigate whether detailed kinematic measures can capture motor impairments and changes that are only partially reflected by established clinical scores.
Detailed description
CIDP is a rare chronic immune-mediated neurological condition that can lead to muscle weakness, sensory disturbances, gait impairment, and limitations in everyday activities. Due to the heterogeneous clinical presentation of CIDP, objective assessment of functional status and longitudinal changes remains challenging. Established clinical measures such as INCAT, I-RODS, MRC sum score, and grip strength provide important information on disability and motor function but may not capture subtle, regional, or multidimensional changes in movement.
Consequently, this study aims to evaluate high-resolution whole-body motion data to assess functional status and longitudinal changes in patients with CIDP. Firstly, sensor-based movement measures will be compared to established clinical scores, strength measurements, and patient-reported outcomes. Secondly, explorative analyses will aim to investigate whether longitudinal changes in movement patterns reflect changes in functional status and whether distinct movement phenotypes can be identified.
Data captured by the whole-body motion-sensing system (Xsens) includes three-dimensional kinematic parameters describing the movement of individual joints and body segments. These include joint angles, movement velocities, range of motion, acceleration, coordination, and side-to-side symmetry. Based on these parameters, multidimensional movement "fingerprints" will be derived to characterize individual motor function. Blood samples will additionally be collected for the analysis of potential biomarkers, including serum neurofilament light chain (sNfL), glial fibrillary acidic protein (GFAP), and proteomic data. The investigators aim to determine whether sensor-based movement patterns can capture regional and gradual motor impairments and whether they provide additional information beyond established clinical outcome measures.
Optionally, explorative analyses will investigate whether characteristic movement phenotypes, such as predominantly upper- or lower-limb, proximal or distal, or asymmetric impairment patterns, can be identified from the sensor data.
Patients will be recruited in Düsseldorf.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CIDP patiens | – | Device: Xsens motion suitCIDP patients undergoing any treatment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- CIDP patients treated at the University Hospital in Düsseldorf.
Key inclusion criteria (4 listed)
- Diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) according to current EAN/PNS diagnostic criteria
- Age ≥18 years
- Ability to understand and perform the standardized movement protocol safely
- Written informed consent prior to study participation
Key exclusion criteria (2 listed)
- Additional neurological diseases that substantially affect motor function as evaluated by the principal investigator
- Relevant orthopedic or rheumatological conditions that substantially influence movement performance as determined by the principal investigator
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Xsens motion suitNon-interventional observational study with whole-body motion assessment to assess functional status and longitudinal changes in patients with CIDP. | Device | CIDP patiens |
Primary outcome
Change in joint angle distributions during standardized movement tasks
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in joint angle distributions across predefined joints and standardized movement tasks from baseline to 6 and 12 months. Joint angle distributions will be characterized using prespecified parameters describing joint kinematics. Changes in these parameters will be assessed at each follow-up visit relative to baseline.
Change in movement velocity
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantitative assessment of joint and limb movement velocities during standardized motor tasks
Change in movement-space volume
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantification of the three-dimensional movement space achieved by individual joints or body segments during standardized movement tasks
Change in coordination patterns
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantitative assessment of intersegmental and inter-joint coordination during standardized movements
Change in side-to-side movement symmetry
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantification of asymmetries between the left and right sides during standardized upper- and lower-limb movements
Change in proximal versus distal movement patterns
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantification of differences in movement characteristics between proximal and distal joints and body segments
Change in upper- versus lower-limb movement patterns
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Quantification of differences in movement characteristics between upper and lower extremities
Change in whole-body movement fingerprint
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in the multidimensional sensor-derived movement fingerprint
Correlation between sensor-derived joint angle distributions and the I-RODS score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Correlation between sensor-derived movement velocity and the I-RODS score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Correlation between sensor-derived whole-body movement fingerprint and the I-RODS score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and activity and participation limitations assessed using the 24-item Inflammatory Rasch-built Overall Disability Scale (I-RODS). The I-RODS total score ranges from 0 to 48, with higher scores indicating better function.
Correlation between sensor-derived joint angle distributions and the INCAT disability score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Correlation between sensor-derived movement velocity and the INCAT disability score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Correlation between sensor-derived whole-body movement fingerprint and the INCAT disability score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and disability assessed using the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale. The INCAT total score ranges from 0 to 10, with lower scores indicating less disability and higher scores indicating greater disability.
Correlation between sensor-derived joint angle distributions and the MRC sum score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Correlation between sensor-derived movement velocity and the MRC sum score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Correlation between sensor-derived whole-body movement fingerprint and the MRC sum score
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and muscle strength assessed using the Medical Research Council (MRC) sum score. The MRC sum score ranges from 0 to 60, with higher scores indicating greater muscle strength.
Correlation between sensor-derived joint angle distributions and handgrip strength
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived joint angle distributions and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
Correlation between sensor-derived movement velocity and handgrip strength
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived movement velocity and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
Correlation between sensor-derived whole-body movement fingerprint and handgrip strength
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Correlation between sensor-derived whole-body movement fingerprint and handgrip strength assessed using a Martin Vigorimeter. Handgrip strength is expressed in kilopascals (kPa), according to the standardized measurement protocol.
7 secondary outcomes
Change in Pittsburgh Sleep Quality Index (PSQI)
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in Fatigue Severity Scale (FSS)
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in WHOQOL-BREF
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Change in blood-based biomarkers
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in standardized walking performance
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in Timed Up and Go performance
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Longitudinal change in sit-to-stand performance
Time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 3
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
RecruitingObservational study
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Charcot-Marie-Tooth, CMT1A
Active, not recruitingPhase 2
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RecruitingPhase 2/3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of CIDP - Chronic Inflammatory Demyelinating Polyneuropathy, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dr. med. Lars Masanneck (0049 211 8117887, neuro-trials@med.uni-duesseldorf.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in joint angle distributions during standardized movement tasks (time frame: Baseline (V1), Month 6 (V2), Month 12 (V3)). The study lists 20 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.